X.e

Autoimmunity - Autoimmune conditions

Corresponds to circulating autoantibodies (ANA, anti-dsDNA, multispecific ANCA). Titers can be very high and/or multispecific and tend to diminish in a few weeks or months upon drug discontinuance. Autoimmunity can be asymptomatic or is with various clinical presentations including pulmonary vascultis or hemorrhage (PMID 20015613). See also under patterns IIIa, IIIb, IIId, Vd, VId, and  Xb, d, h, j, m, s, x, y, ac, ah, am, ao, aw, ax, ay

Last update : 01/01/1970
 

Causative drugs

18

Abatacept

1

Alemtuzumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways) X.ac X - Systemic conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS) X.an X - Systemic conditions, syndromes and reactions
X.an - Cytokine release syndrome XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic) XV.a XV - Pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib) XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection
2

Antithyroid drugs

1

Antiviral therapy/agents (direct-acting) against hepatitis C virus

1

Breast implants/prosthesis

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.n I - Interstitial/parenchymal lung disease
I.n - Pulmonary alveolar proteinosis (PAP) I.al I - Interstitial/parenchymal lung disease
I.al - Silicone pneumonitis - 'Silicone lung' I.am I - Interstitial/parenchymal lung disease
I.am - Siliconoma III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH) V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion V.v V - Pleural and/or pericardial involvement
V.v - Silicone pleural effusion V.w V - Pleural and/or pericardial involvement
V.w - Silicone pleural nodules - Pleural siliconomas VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions X.h X - Systemic conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) X.j X - Systemic conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like granulomatous reaction (endo-/extrathoracic) X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative) X.q X - Systemic conditions, syndromes and reactions
X.q - Systemic inflammatory response X.s X - Systemic conditions, syndromes and reactions
X.s - Vasculitis, pulmonary/systemic (ANCA-positive) X.ad X - Systemic conditions, syndromes and reactions
X.ad - Skin purpura, ecchymoses or necrosis XIII.f XIII - Neoplastic conditions
XIII.f - Fibromatosis of the chest wall XIII.h XIII - Neoplastic conditions
XIII.h - Pulmonary nodular lymphoid hyperplasia XIII.i XIII - Neoplastic conditions
XIII.i - Breast implant-associated anaplastic large cell lymphoma XV.bn XV - Pathology
XV.bn - Path: Silicone in lung tissue, pulmonary vasculature or pleura XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVI.av XVI - Imaging
XVI.av - Imaging: Displacement/migration of breast implant XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy XVIII.c XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.c - Eye catcher: A displaced breast implant
1

Etanercept

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.q I - Interstitial/parenchymal lung disease
I.q - Pulmonary nodulosis I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus) V.f V - Pleural and/or pericardial involvement
V.f - Pneumothorax V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative) VI.a VI - Pulmonary vasculopathies
VI.a - Venous thrombo-embolism - Pulmonary embolism VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) VIII.a VIII - Central, upper, large airway, pharyngeal involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) IX.q IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.q - Obstructive sleep apnea X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis X.j X - Systemic conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like granulomatous reaction (endo-/extrathoracic) X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative) X.s X - Systemic conditions, syndromes and reactions
X.s - Vasculitis, pulmonary/systemic (ANCA-positive) X.ar X - Systemic conditions, syndromes and reactions
X.ar - Relapse/flare/onset of Crohn's disease XI.ad XI - Miscellaneous
XI.ad - Granulomas on tattoo edges XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis XV.a XV - Pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.ba XV - Pathology
XV.ba - Path: Granulomatous lymphadenopathy XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo) XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection XVII.ab XVII - Infections & related conditions
XVII.ab - Protozoan infection (incl. leishmaniasis)
3

Hydralazine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH) III.b III - Pulmonary/alveolar hemorrhage
III.b - Pneumorenal syndrome III.d III - Pulmonary/alveolar hemorrhage
III.d - Alveolar hemorrhage, diffuse (ANCA-positive/-related) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus) V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (may cause acute chest pain (see also under XIc) V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative) VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis VIII.a VIII - Central, upper, large airway, pharyngeal involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) VIII.c VIII - Central, upper, large airway, pharyngeal involvement
VIII.c - Upper airway obstruction other than angioedema or hematoma VIII.h VIII - Central, upper, large airway, pharyngeal involvement
VIII.h - Vocal cord dysfunction, adduction, closure X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome) X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative) X.o X - Systemic conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome) X.s X - Systemic conditions, syndromes and reactions
X.s - Vasculitis, pulmonary/systemic (ANCA-positive) X.s X - Systemic conditions, syndromes and reactions
X.s - Vasculitis, pulmonary/systemic (ANCA-positive) X.ak X - Systemic conditions, syndromes and reactions
X.ak - Dual MPO-/PR3-ANCA systemic disease/vasculitis XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis - Pericardial effusion - Tamponade XII.k XII - Cardiovascular involvement / toxicity
XII.k - Pericardial thickening - Constrictive pericarditis XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL)
2

Hydrochlorothiazide

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.d II - Pulmonary edema - Acute lung injury - ARDS
II.d - Pulmonary edema, cardiogenic II.f II - Pulmonary edema - Acute lung injury - ARDS
II.f - Hypoxemia, low saturation (may occur in isolation) II.i II - Pulmonary edema - Acute lung injury - ARDS
II.i - Flash (fulminate) pulmonary edema II.r II - Pulmonary edema - Acute lung injury - ARDS
II.r - Interstitial pulmonary edema V.j V - Pleural and/or pericardial involvement
V.j - Pericardial effusion (w/wo tamponade (see under XIIc)) X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions X.u X - Systemic conditions, syndromes and reactions
X.u - Multiple organ dysfunction/failure (MODS/MOF) XI.b XI - Miscellaneous
XI.b - Noncardiac chest pain (acute or subacute). Lone or prominent XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis - Pericardial effusion - Tamponade XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock XXI.a XXI - Rechallenge data
XXI.a - Has led to near-fatal or fatal relapse
1

Immune checkpoint inhibitors (ICPI) - ICPI combinatorial Rx

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified) I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id) I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical) I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis I.aj I - Interstitial/parenchymal lung disease
I.aj - Shrinking lung syndrome II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.m III - Pulmonary/alveolar hemorrhage
III.m - Coagulopathy V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion V.j V - Pleural and/or pericardial involvement
V.j - Pericardial effusion (w/wo tamponade (see under XIIc)) VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome) X.c X - Systemic conditions, syndromes and reactions
X.c - Capillary leak syndrome (CLS) X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways) X.h X - Systemic conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) X.j X - Systemic conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like granulomatous reaction (endo-/extrathoracic) X.am X - Systemic conditions, syndromes and reactions
X.am - Immune-related adverse effect/toxicity X.aw X - Systemic conditions, syndromes and reactions
X.aw - Connective tissue disease XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XI.y XI - Miscellaneous
XI.y - Adrenal suppression XI.ag XI - Miscellaneous
XI.ag - Vertebral compression fracture XI.au XI - Miscellaneous
XI.au - Graft vs. host disease in transplant recipients XI.av XI - Miscellaneous
XI.av - Deterioration of graft function in SOT recipients XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.s XII - Cardiovascular involvement / toxicity
XII.s - Heart block (bundle branch- or AV-) XII.ai XII - Cardiovascular involvement / toxicity
XII.ai - Cardiotoxicity XV.a XV - Pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib) XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.ba XV - Pathology
XV.ba - Path: Granulomatous lymphadenopathy XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo) XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
2

Infliximab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified) I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus) VI.a VI - Pulmonary vasculopathies
VI.a - Venous thrombo-embolism - Pulmonary embolism VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome) X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways) X.h X - Systemic conditions, syndromes and reactions
X.h - Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) X.j X - Systemic conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like granulomatous reaction (endo-/extrathoracic) X.s X - Systemic conditions, syndromes and reactions
X.s - Vasculitis, pulmonary/systemic (ANCA-positive) X.ah X - Systemic conditions, syndromes and reactions
X.ah - Granulomatosis with polyangiitis (w/wo ANCA) or flare of X.ar X - Systemic conditions, syndromes and reactions
X.ar - Relapse/flare/onset of Crohn's disease XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis - Pericardial effusion - Tamponade XV.a XV - Pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.cf XV - Pathology
XV.cf - Path: Pleural granulomas XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo) XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection XVII.n XVII - Infections & related conditions
XVII.n - Legionella pneumophila pneumonia XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary) XVII.y XVII - Infections & related conditions
XVII.y - Cryptococcus pulmonary infection XVII.z XVII - Infections & related conditions
XVII.z - Histoplamosis (reactivation) XVII.ac XVII - Infections & related conditions
XVII.ac - Actinomycosis
2

Ipilimumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.v I - Interstitial/parenchymal lung disease
I.v - Altered lung function/PFTs (can be subclinical) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative) VII.e VII - Mediastinal involvement
VII.e - Granulomatous mediastinal lymphadenopathy IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemidiaphragmatic paralysis IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis (may cause neuromuscular ARF) IX.ab IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ab - Guillain-Barré (or GB-like) syndrome X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome) X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways) X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like granulomatous reaction (endo-/extrathoracic) X.l X - Systemic conditions, syndromes and reactions
X.l - Systemic granulomatosis other than Xk X.o X - Systemic conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome) X.am X - Systemic conditions, syndromes and reactions
X.am - Immune-related adverse effect/toxicity XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis - Pericardial effusion - Tamponade XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XVI.bh XVI - Imaging
XVI.bh - Imaging: F18-PET scan positive lympadenopathy XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes
1

Minocycline

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.aj I - Interstitial/parenchymal lung disease
I.aj - Shrinking lung syndrome II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury IV.d IV - Airway involvement
IV.d - Cough (lone) V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus) V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative) VII.a VII - Mediastinal involvement
VII.a - Lymphadenopathy (intrathoracic) X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome) X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways) X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative) X.o X - Systemic conditions, syndromes and reactions
X.o - Neutrophilic dermatosis (Pyoderma, Sweet syndrome) X.s X - Systemic conditions, syndromes and reactions
X.s - Vasculitis, pulmonary/systemic (ANCA-positive) X.v X - Systemic conditions, syndromes and reactions
X.v - Systemic eosinophilic syndrome w/wo vasculitis (see also Xa) X.aj X - Systemic conditions, syndromes and reactions
X.aj - Polyarteritis nodosa-like condition XI.b XI - Miscellaneous
XI.b - Noncardiac chest pain (acute or subacute). Lone or prominent XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain (see also under Vi) XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericarditis - Pericardial effusion - Tamponade XII.d XII - Cardiovascular involvement / toxicity
XII.d - Myocarditis XII.as XII - Cardiovascular involvement / toxicity
XII.as - Giant cell myocarditis XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.ac XV - Pathology
XV.ac - Path: Pulmonary vasculitis other than capillaritis XV.ad XV - Pathology
XV.ad - Path: Eosinophilic vasculitis XV.af XV - Pathology
XV.af - Path: Granulomatous pulmonary vasculitis XV.ch XV - Pathology
XV.ch - Path: Brownish macrophages in alveolar spaces XVI.e XVI - Imaging
XVI.e - Imaging: Pulmonary opacities with a subpleural distribution XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils
2

Nitrofurantoin

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified) I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.j II - Pulmonary edema - Acute lung injury - ARDS
II.j - Transient pulmonary opacities III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus) V.i V - Pleural and/or pericardial involvement
V.i - Pleuritis (may cause acute chest pain (see also under XIc) VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis VIII.b VIII - Central, upper, large airway, pharyngeal involvement
VIII.b - Hematoma of/around the airway wall potentially causing UAO IX.i IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.i - Respiratory arrest - Apnea X.a X - Systemic conditions, syndromes and reactions
X.a - DRESS (drug rash eosinophilia and hypersensitivity syndrome) X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis X.s X - Systemic conditions, syndromes and reactions
X.s - Vasculitis, pulmonary/systemic (ANCA-positive) XI.b XI - Miscellaneous
XI.b - Noncardiac chest pain (acute or subacute). Lone or prominent XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain (see also under Vi) XV.a XV - Pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib) XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.h XV - Pathology
XV.h - Path: Fibrotic NSIP pattern XV.j XV - Pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern) XV.k XV - Pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern) XV.x XV - Pathology
XV.x - Path: Acute or subacute bronchiolitis (see also IVc, IVi) XV.ac XV - Pathology
XV.ac - Path: Pulmonary vasculitis other than capillaritis XV.af XV - Pathology
XV.af - Path: Granulomatous pulmonary vasculitis XV.bi XV - Pathology
XV.bi - Path: Giant-cell interstitial pneumonia (GIP)-pattern XV.bl XV - Pathology
XV.bl - Path: Resolving alveolar damage XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.f XVI - Imaging
XVI.f - Imaging: Bibasilar opacities/shadowing XVI.l XVI - Imaging
XVI.l - Imaging: Peribronchovascular areas of consolidation XVI.bp XVI - Imaging
XVI.bp - Imaging: Reverse ventilation-perfusion mismatch
2

Paraffin - Vaseline - Oil - Lipids (Mineral or other). P.o./aspirated

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified) I.j I - Interstitial/parenchymal lung disease
I.j - Lipoid pneumonia, exogenous I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses I.z I - Interstitial/parenchymal lung disease
I.z - Areas of consolidation I.ap I - Interstitial/parenchymal lung disease
I.ap - Paraffinoma - Lipidoma (ELP in the form of a nodule or mass) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.c III - Pulmonary/alveolar hemorrhage
III.c - Hemoptysis IV.w IV - Airway involvement
IV.w - Plugs/casts in the airways X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XV.h XV - Pathology
XV.h - Path: Fibrotic NSIP pattern XV.p XV - Pathology
XV.p - Path: Exogenous lipoid pneumonia XV.q XV - Pathology
XV.q - Path: Foreign body deposits/reaction XVI.a XVI - Imaging
XVI.a - Imaging: Diffuse haze XVI.f XVI - Imaging
XVI.f - Imaging: Bibasilar opacities/shadowing XVI.i XVI - Imaging
XVI.i - Imaging: An area or areas of involvement with a recognizable anatomic distribution XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVI.n XVI - Imaging
XVI.n - Imaging: Intralobular septal thickening - Crazy paving XVI.r XVI - Imaging
XVI.r - Imaging: An area or areas of involvement with low attenuation numbers XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or nodules XVI.z XVI - Imaging
XVI.z - Imaging: A large nodule or mass XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating lung nodule or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.az XVI - Imaging
XVI.az - Imaging: Solitary pulmonary nodule XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection XVIII.r XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.r - Eye catcher: A milky, cloudy or lumpy BAL fluid XIX.h XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.h - BAL: Exogenous (foreign) lipids in BAL cells XIX.j XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.j - BAL: Free exogenous lipids in supernatant XXIV.f XXIV - Veterinary medicine
XXIV.f - Veterinary: Exogenous lipoid pneumonia
1

Penicillamine

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH) III.b III - Pulmonary/alveolar hemorrhage
III.b - Pneumorenal syndrome III.d III - Pulmonary/alveolar hemorrhage
III.d - Alveolar hemorrhage, diffuse (ANCA-positive/-related) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.c IV - Airway involvement
IV.c - Obliterative bronchiolitis (see also IVn) IV.n IV - Airway involvement
IV.n - Obstructive airway dysfunction (see also IVc) V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF) IX.r IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.r - Myasthenia gravis (may cause neuromuscular ARF) X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions X.j X - Systemic conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.s X - Systemic conditions, syndromes and reactions
X.s - Vasculitis, pulmonary/systemic (ANCA-positive) X.ac X - Systemic conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS) XI.t XI - Miscellaneous
XI.t - Yellow nail syndrome XV.z XV - Pathology
XV.z - Path: Constrictive obliterative broncholitis (see also IVc, IVn) XVII.w XVII - Infections & related conditions
XVII.w - Hypogammaglobulinemia - Antibody deficiency
1

Propylthiouracil (PTU)

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH) III.b III - Pulmonary/alveolar hemorrhage
III.b - Pneumorenal syndrome III.d III - Pulmonary/alveolar hemorrhage
III.d - Alveolar hemorrhage, diffuse (ANCA-positive/-related) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.r IV - Airway involvement
IV.r - Airway pigmentation (black, bluish, petechial) V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus) V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericardial effusion (ANA unknown or negative) V.u V - Pleural and/or pericardial involvement
V.u - Eosinophilic pleuritis VI.d VI - Pulmonary vasculopathies
VI.d - Pulmonary vasculitis or capillaritis X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative) X.s X - Systemic conditions, syndromes and reactions
X.s - Vasculitis, pulmonary/systemic (ANCA-positive) X.x X - Systemic conditions, syndromes and reactions
X.x - Subclinical ANCA positivity X.ak X - Systemic conditions, syndromes and reactions
X.ak - Dual MPO-/PR3-ANCA systemic disease/vasculitis XI.n XI - Miscellaneous
XI.n - Neutropenia, agranulocytosis (w/wo infection/sepsis) XV.a XV - Pathology
XV.a - Path: Cellular NSIP pattern (see also Ia, Ib) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.h XV - Pathology
XV.h - Path: Fibrotic NSIP pattern XV.an XV - Pathology
XV.an - Path: Eosinophilic pleuritis
2

TNF-alpha antagonists/inhibitors

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute, severe (may occasion an ARDS picture) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis (Not otherwise specified) I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.q I - Interstitial/parenchymal lung disease
I.q - Pulmonary nodulosis I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.y I - Interstitial/parenchymal lung disease
I.y - Progression, acceleration or exacerbation of preexisting ILD/fibrosis III.a III - Pulmonary/alveolar hemorrhage
III.a - Alveolar hemorrhage, diffuse (DAH) III.d III - Pulmonary/alveolar hemorrhage
III.d - Alveolar hemorrhage, diffuse (ANCA-positive/-related) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus) IX.q IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.q - Obstructive sleep apnea IX.t IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.t - CNS involvement/dysfunction/damage X.b X - Systemic conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.d X - Systemic conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.e X - Systemic conditions, syndromes and reactions
X.e - Autoimmunity - Autoimmune conditions X.f X - Systemic conditions, syndromes and reactions
X.f - Anaphylaxis X.g X - Systemic conditions, syndromes and reactions
X.g - Hypersensitivity reactions (may involve skin, throat and/or airways) X.j X - Systemic conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.k X - Systemic conditions, syndromes and reactions
X.k - Sarcoid-like granulomatous reaction (endo-/extrathoracic) X.m X - Systemic conditions, syndromes and reactions
X.m - Pulmonary and/or systemic vasculitis (ANCA status MPO, unknown or negative) X.p X - Systemic conditions, syndromes and reactions
X.p - Serum sickness-like reaction X.s X - Systemic conditions, syndromes and reactions
X.s - Vasculitis, pulmonary/systemic (ANCA-positive) X.x X - Systemic conditions, syndromes and reactions
X.x - Subclinical ANCA positivity X.ae X - Systemic conditions, syndromes and reactions
X.ae - Antisynthetase antibodies (ASA) - ASA syndrome XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left ventricular dysfunction/failure XV.ba XV - Pathology
XV.ba - Path: Granulomatous lymphadenopathy XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infection XVII.d XVII - Infections & related conditions
XVII.d - Pneumocystis jiroveci pulmonary colonization XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, extrapulmonary, reactivation or de novo) XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection XVII.m XVII - Infections & related conditions
XVII.m - Fungal airway infection XVII.n XVII - Infections & related conditions
XVII.n - Legionella pneumophila pneumonia XVII.q XVII - Infections & related conditions
XVII.q - Viral pneumonia XVII.r XVII - Infections & related conditions
XVII.r - Fungal infection (pulmonary/extrapulmonary) XVII.v XVII - Infections & related conditions
XVII.v - Strongyloides stercoralis hyperinfection (w/wo DAH) XVII.y XVII - Infections & related conditions
XVII.y - Cryptococcus pulmonary infection XVII.z XVII - Infections & related conditions
XVII.z - Histoplamosis (reactivation) XVII.ab XVII - Infections & related conditions
XVII.ab - Protozoan infection (incl. leishmaniasis) XVII.ak XVII - Infections & related conditions
XVII.ak - Mycobacterium leprae infection (Leprosy)
3

Trimethoprim sulfamethoxazole

1

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies